IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
Key Highlights
- ➤IDEAYA plans approximately 90-patient GEP-NEC cohort supporting potential accelerated approval
- ➤Randomized Phase 3 NEC trial targets full approval, with OS as primary endpoint
- ➤IDE849 delivered 52.6% ORR and 7.0-month median PFS in 2L+ NEC
- ➤IDEAYA targets two randomized Phase 3 trials and a GEP-NEC cohort by end-2026
- ➤Grade ≥3 TRAE rates were 5% at 2.4 mg/kg and 22.2% at 3.5 mg/kg
Expert Statements
Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences
“NEC is an aggressive disease with limited treatment options after first-line platinum-based chemotherapy. Our recent IDE849 data presented at ESMO in refractory NEC provides strong support for the clinical benefit that a DLL3-targeted ADC may offer for patients with this devastating disease.”
Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences
“In light of the fast-evolving landscape of DLL3-targeting agents we have completed two Type C meetings with the U.S. FDA and leading clinical investigators globally to align on the study designs for our registrational trials in both refractory NEC and ES-SCLC, including for accelerated approval, to ensure IDE849 is well positioned to become a viable new potential treatment option for patients with these difficult to treat cancers.”
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas PR Newswire
* Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpoint * Randomized Phase 3 trial in multiple refractory NEC subtypes, including GEP-NEC and LC-NEC, is planned to support full approval, with OS as the primary endpoint * IDE849 has demonstrated a 52.6% ORR (10/19), median PFS of 7.0 months, and an estimated 9-month OS rate of 82.4% in 2L+ NEC * Global Phase 1/2 trial of IDE849 has shown a Grade ≥3 TRAE rate of 5% (1/20) and 22.2% (4/18) at the 2.4 mg/kg and 3.5 mg/kg expansion doses, respectively * IDEAYA is targeting to initiate two randomized Phase 3 registrational trials in the refractory NEC and post-Imdelltra ES-SCLC settings, and a potential registration-enabling single-arm extension cohort in refractory GEP-NEC, by the end of 2026 SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of transformative therapies to address unmet medical needs in cancer, today announced its registrational strategy for IDE849, a potential best-in-class delta-like ligand 3 (DLL3)-targeting Topo-I-payload antibody drug conjugate (ADC), in previously treated (2L+) neuroendocrine carcinomas (NEC). IDEAYA is planning to initiate registrational trials in both previously treated NEC and extensive-stage small cell lung cancer (ES-SCLC) by the end of the year.
Get started
Create a free account to read the full story.
